VSIR and cancer: Therefore, simultaneous blockade of PD-L1 and VISTA could be beneficial for cancer immunotherapy, and a number of antibodies targeting VISTA are in pre-clinical development for potential use in combination with anti-PD-1/PD-L1 antibodies in the clinic.